Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Frequently asked questions
What sector does Renalytix Plc (RNLXY) operate in?
Renalytix Plc belongs to the Other sector and operates in the industry.
What is Renalytix Plc (RNLXY) current stock price?
As of the latest data, Renalytix Plc stock price is $2.78, with a previous close of $2.64. Renalytix Plc gained $0.14 in the last trading session, representing a 5.11% increase.
What is Renalytix Plc (RNLXY) current market capitalization?
Renalytix Plc market cap is approximately 606.36 million.
What is Renalytix Plc (RNLXY) Earnings Per Share (EPS)?
The trailing EPS is -$3.50.
Does Renalytix Plc (RNLXY) pay dividends?
No. Renalytix Plc does not pay a dividend.
What is Renalytix Plc (RNLXY) beta (volatility) score?
Renalytix Plc has a beta of 1.810, suggesting it is more volatile than the market.
